StockIQ.techPro Medicus Limited (PME.AX) Stock Analysis
Free AI-powered analysis and research for Pro Medicus Limited stock
Sector: Healthcare
PME.AX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Pro Medicus Limited scores 95/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 51% of its 52-week range, down 26.9% over the past year. Latest reported figures show a profit margin of 101.4%, return on equity of 75.0% and revenue growth of +18.2%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (77.2): -10
- Strong Revenue Growth (18.2%): +8
- Excellent Profit Margin (101.4%): +10
- Low Debt (0.00 D/E): +8
- Strong Liquidity (6.85 Current Ratio): +8
- Excellent ROE (75.0%): +8
- High P/B (45.46): -5
- Strong Long-term Uptrend: +8
- Severe Underperformance (-26.9% over 1 year): -10
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full PME.AX report
Pro Medicus Limited (PME.AX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze PME.AX Now →📰 Latest Update
Pro Medicus (ASX:PME) Shares May Look Fully Priced As A$24 Million Deal Lands
Mon, October 19, 2026 at 4:14 PM UTC 2 min read
Pro Medicus (ASX: PME) has announced a A$24 million deal, which some analysts believe may indicate that the stock is fully priced. This development is significant for investors as it raises questions about the company's growth potential and whether the current share price reflects its future earnings prospects. Investors should consider the implications of this deal on Pro Medicus's valuation and market position moving forward.